GLYC - GlycoMimetics Positive Data For AML Therapy Increasingly Likely March, 16 2022 11:54 AM GlycoMimetics Inc. Data delay for AML therapy is most likely due to a positive OS trend. Uproleselan AML trial is fully enrolled with data due in 2023. GlycoMimetics is woefully undervalued, but not without risk. For further details see: GlycoMimetics Positive Data For AML Therapy Increasingly Likely